AstraZeneca plc vs Google Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Google Inc trades at $342.39 (market cap $4.20T). The key difference: Google Inc is far larger — about 16.9× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | GOOG | |
|---|---|---|
Market Cap | $248.14B | $4.20T |
Sector | Health | Technology |
52-Week High | $209.48 | $399.06 |
52-Week Low | $147.06 | $200.19 |
Enterprise Value | $275.41B | $4.09T |
Dividend Yield | 2.01% | 0.26% |
Volume | — | 1,511,127 |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Alphabet (GOOG) trades at $342.71, down 3.69% on the day, with technical indicators showing a bearish trend near support at $340. The company reported strong fundamentals with Q2 2026 EPS of $9.11 beating expectations, revenue growth to $402.84B in 2025, and robust profitability margins. Recent news highlights AI advancements, including Gemini reaching 1 billion users, but also regulatory scrutiny from French media.
The stock presents a compelling long-term opportunity with a consensus price target of $431.67, representing 26% upside, supported by 87% analyst buy ratings. Risks include high capital expenditure forecasts up to $205B for 2026, competitive AI pressures, and ongoing regulatory challenges. Investors should weigh strong cash flow generation against aggressive investment cycles.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →